With 16.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.85 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.23 whereas the lowest price it dropped to was $2.58. The 52-week range on SANA shows that it touched its highest point at $7.40 and its lowest point at $1.26 during that stretch. It currently has a 1-year price target of $9.33. Beta for the stock currently stands at 1.79.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was up-trending over the past week, with a rise of 0.39%, but this was up by 32.65% over a month. Three-month performance surged to 12.55% while six-month performance rose 36.13%. The stock gained 59.51% in the past year, while it has lost -54.23% so far this year. A look at the trailing 12-month EPS for SANA yields -0.88 with Next year EPS estimates of -0.71. For the next quarter, that number is -0.20. This implies an EPS growth rate of 34.68% for this year and 6.84% for next year. EPS is expected to grow by 14.07% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -10.60%.
Float and Shares Shorts:
At present, 225.46 million SANA shares are outstanding with a float of 125.44 million shares on hand for trading. On 2025-05-30, short shares totaled 44.26 million, which was 1962.0001000000002 higher than short shares on 1745971200. In addition to Dr. Steven D. Harr M.D. as the firm’s President, CEO & Director, Mr. Bernard J. Cassidy J.D. serves as its Executive VP, General Counsel & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.89387 of SANA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SANA reported revenue of $0.0 and operating income of -$50630000.0. The EBITDA in the recently reported quarter was -$46981000.0 and diluted EPS was -$0.21.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.12821 being high and -$1.25357 being low. For SANA, this leads to a yearly average estimate of -$1.18607.
